S046 What's New in Dermatopathology
DESCRIPTION
This symposium provides information regarding advances in key areas of dermatopathology. Cutaneous neoplasia, inflammatory skin disease, molecular techniques, computer assisted diagnosis/artificial intelligence, translational research, and cutaneous infections will be covered. Attendees will leave the session with updated knowledge in dermatopathology.
LEARNING OBJECTIVES
Describe new advances in cutaneous neoplasia, including melanocytic tumors and adnexal neoplasms
Discuss recent developments in diagnosing inflammatory skin disease and cutaneous drug reactions
Describe recent developments in artificial intelligence in the field of dermatopathology
SCHEDULE
1:00 PM
What's new in oncodermatology?
Anisha Patel, MD, FAAD
1:20 PM
What's new in digital pathology?
Corey J. Georgesen, MD, FAAD
1:40 PM
What's new in inpatient dermatology?
Kiran Motaparthi, MD, FAAD
2:00 PM
Q&A
Anisha Patel, MD, FAAD, Corey J. Georgesen, MD, FAAD, Kiran Motaparthi, MD, FAAD
2:10 PM
What's new in adnexal neoplasms?
Jeffrey P. North, MD, FAAD
2:30 PM
What's new in keratinocytic carcinoma?
Kenneth Y. Tsai, MD, PhD, FAAD
2:50 PM
Q&A
Jeffrey P. North, MD, FAAD, Kenneth Y. Tsai, MD, PhD, FAAD
3:00 PM
What's new in viral infectious diseases?
Travis W Vandergriff, MD, FAAD
3:20 PM
What's new in nail pathology?
Molly A. Hinshaw, MD, FAAD
3:40 PM
What's new in rashes?
Ronald P. Rapini, MD, FAAD
DIRECTOR
Anisha Patel, MD, FAAD
SPEAKERS
Corey J. Georgesen, MD, FAAD
Molly A. Hinshaw, MD, FAAD
Kiran Motaparthi, MD, FAAD
Jeffrey P. North, MD, FAAD
Ronald P. Rapini, MD, FAAD
Kenneth Y. Tsai, MD, PhD, FAAD
Travis W Vandergriff, MD, FAAD
DISCLOSURES
Corey J. Georgesen, MD, FAAD
No financial relationships exist with ineligible companies.
Molly A. Hinshaw, MD, FAAD
BiaCure Therapies Inc – Founder(Stock);
Kiran Motaparthi, MD, FAAD
Castle Biosciences, Inc – Consultant(Fees), Investigator(Grants/Research Funding); Proscia – Investigator(Grants/Research Funding);
Jeffrey P. North, MD, FAAD
Johnson & Johnson Pharmaceutical Research & Development – Consultant (1099 relationship)(Fees);
Anisha Patel, MD, FAAD
Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Chugai Pharmaceutical Co., Ltd – Speaker/Faculty Education(Other Financial Benefit); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); Hoth Therapeutics – Investigator(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); OnQuality Pharmaceuticals, Ltd. – Consultant(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);
Ronald P. Rapini, MD, FAAD
No financial relationships exist with ineligible companies.
Kenneth Y. Tsai, MD, PhD, FAAD
3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); Ankyra Therapeutics – Independent Contractor(Grants/Research Funding); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); Regeneron Pharmaceuticals Inc – Advisory Board(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);
Travis W Vandergriff, MD, FAAD
Elsevier Inc. – Independent Contractor(Honoraria);